Cancer Family
Digestive System Neuroendocrine Neoplasm
CI-CAN-00000164Explore in graph →
Non-malignant76 active trials2 evidence items
- NCIt
- C27721
Loading cancer entity…
Cancer Family
CI-CAN-00000164Explore in graph →
Clinical trials
295 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 0 | Jul 31, 2024 |
| clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT04915144 | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | withdrawn | Phase 2 | 0 | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03053284 | Pasireotide in Hyperinsulinemic Hypoglycemia | withdrawn | Phase 2 | 0 | Montefiore Medical CenterOTHER | 0 | May 14, 2021 | clinicaltrials |
| NCT04065165 | Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome(TELEFIRST) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Oct 26, 2024source: clinicaltrials